LGND: 2025 Results & Focus on Qtorin
By John Vandermosten, CFANASDAQ:LGNDREAD THE FULL LGND RESEARCH REPORTLigand Pharmaceuticals, Inc. (NASDAQ:LGND) reported 2025 results with revenues of $268 million…
28,980$
6,43%
Echtzeit-Aktienkurs Travere Therapeutics Inc.
Bid:
Ask:
Nachrichten zur Travere Therapeutics Inc. Aktie
Travere Therapeutics, Inc. (TVTX) Q4 2025 Earnings Call Transcript
…
TVTX Stock Falls as FDA Extends Review Timeline for Filspari sNDA
Travere Therapeutics shares fall after the FDA extends its review timeline for Filsparis sNDA in FSGS, pushing the decision date…
Travere Therapeutics stock hits 52-week high at 37.12 USD By Investing.com
Travere Therapeutics stock hits 52-week high at 37.12 USD…
Travere Therapeutics, Inc. (TVTX) Q3 2025 Earnings Call Transcript
…
Travere Therapeutics soars as FILSPARI sales surge in third quarter By Investing.com
Travere Therapeutics soars as FILSPARI sales surge in third quarter…
Lennar, Jabil, Nvidia
Wall Streets main indexes were on track for a lower open on Tuesday as the Israel-Iran conflict entered its fifth…
Travere Therapeutics stock falls on FDA review setback By Investing.com
Travere Therapeutics stock falls on FDA review setback…
Travere Therapeutics, Inc. 2025 Q1 - Results - Earnings Call Presentation
…
Travere Therapeutics, Inc. (TVTX) Q1 2025 Earnings Call Transcript
…
Travere Therapeutics, Inc. (TVTX) Q4 2024 Earnings Call Transcript
…
Travere Therapeutics stock rises on sNDA submission plans for FILSPARI By Investing.com
Travere Therapeutics stock rises on sNDA submission plans for FILSPARI…
Travere Therapeutics to Present at Upcoming Investor Conferences
SAN DIEGO, Nov. 25, 2024 (GLOBE NEWSWIRE) -- Travere Therapeutics, Inc., (NASDAQ: TVTX) today announced that company management…
Travere Therapeutics Announces Pricing of Public Offering of Common Stock
SAN DIEGO, Nov. 07, 2024 (GLOBE NEWSWIRE) -- Travere Therapeutics, Inc. (Nasdaq: TVTX) today announced the pricing of…
Travere Therapeutics and CSL Vifor Announce Swissmedic Approval of FILSPARI® (sparsentan) for the Treatment of IgA Nephropathy
Travere Therapeutics and CSL Vifor announce swissmedic approval of FILSPARI® (sparsentan) for the treatment of IgA nephropathy.…
TVTX INVESTOR ALERT: Bronstein, Gewirtz and Grossman, LLC Announces an Investigation into Travere Therapeutics, Inc. and Encourages Investors to Contact the Firm
NEW YORK, Oct. 13, 2024 (GLOBE NEWSWIRE) -- Attorney Advertising -- Bronstein, Gewirtz & Grossman, LLC is investigating…
After-hours movers: Costco, Scholastic Corp, Travere Therapeutics By Investing.com
After-hours movers: Costco, Scholastic Corp, Travere Therapeutics…
Travere Therapeutics Reports Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)
SAN DIEGO, Sept. 12, 2024 (GLOBE NEWSWIRE) -- Travere Therapeutics, Inc., (NASDAQ: TVTX) today announced that on September…
Travere Therapeutics to Present at the 2024 Cantor Global Healthcare Conference
SAN DIEGO, Sept. 10, 2024 (GLOBE NEWSWIRE) -- Travere Therapeutics, Inc., (NASDAQ: TVTX) today announced that company management…
Travere Therapeutics, Inc. (TVTX) Q2 2024 Earnings Call Transcript
…
Travere Therapeutics, Inc. (TVTX) Q1 2024 Earnings Call Transcript
…
Travere Therapeutics to Report First Quarter 2024 Financial Results
SAN DIEGO, Calif., April 29, 2024 (GLOBE NEWSWIRE) -- Travere Therapeutics, Inc. (NASDAQ: TVTX) today announced it will…
Travere Therapeutics Reports Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)
SAN DIEGO, March 13, 2024 (GLOBE NEWSWIRE) -- Travere Therapeutics, Inc. (NASDAQ: TVTX) today announced that on March…